Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Investment analysts at Leerink Swann reduced their FY2018 EPS estimates for shares of Celldex Therapeutics in a note issued to investors on Wednesday, according to Zacks Investment Research. Leerink Swann analyst S. Fernandez now expects that the biopharmaceutical company will post earnings of ($1.06) per share for the year, down from their previous estimate of ($0.94). Leerink Swann has a “Market Perform” rating and a $3.00 price objective on the stock. Leerink Swann also issued estimates for Celldex Therapeutics’ FY2019 earnings at ($0.77) EPS and FY2020 earnings at ($0.73) EPS.
Other equities analysts also recently issued reports about the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $9.00 price target on shares of Celldex Therapeutics in a report on Wednesday, March 7th. HC Wainwright set a $10.00 price target on Celldex Therapeutics and gave the company a “buy” rating in a report on Friday, February 9th. BidaskClub upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, January 5th. Finally, WBB Securities reiterated a “buy” rating and issued a $10.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, December 6th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. Celldex Therapeutics presently has a consensus rating of “Hold” and an average target price of $6.38.
Shares of CLDX stock traded up $0.02 on Monday, reaching $2.45. The company had a trading volume of 836,445 shares, compared to its average volume of 1,393,346. The firm has a market capitalization of $337.17, a P/E ratio of -3.27 and a beta of 2.63. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $3.75.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.08. The firm had revenue of $3.50 million during the quarter, compared to the consensus estimate of $1.49 million. Celldex Therapeutics had a negative return on equity of 44.64% and a negative net margin of 730.06%. The firm’s quarterly revenue was up 87.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.30) earnings per share.
Hedge funds and other institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC purchased a new stake in Celldex Therapeutics in the third quarter valued at approximately $101,000. OxFORD Asset Management LLP purchased a new stake in shares of Celldex Therapeutics during the third quarter worth approximately $122,000. Teacher Retirement System of Texas raised its stake in shares of Celldex Therapeutics by 325.0% during the fourth quarter. Teacher Retirement System of Texas now owns 43,253 shares of the biopharmaceutical company’s stock worth $123,000 after purchasing an additional 33,077 shares during the last quarter. Voya Investment Management LLC raised its stake in shares of Celldex Therapeutics by 17.4% during the second quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 7,499 shares during the last quarter. Finally, MetLife Investment Advisors LLC purchased a new stake in shares of Celldex Therapeutics during the fourth quarter worth approximately $187,000. Institutional investors own 55.45% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/21/celldex-therapeutics-inc-forecasted-to-earn-fy2018-earnings-of-1-06-per-share-cldx.html.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.